Trial Profile
A Phase I Study of Ixazomib and Erlotinib in Advanced Solid Tumor Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Ixazomib (Primary)
- Indications Adenocarcinoma; Alveolar soft part sarcoma; Carcinoma; Cervical cancer; Chondrosarcoma; Clear cell sarcoma; Colon cancer; Colorectal cancer; Duodenal cancer; Endometrial cancer; Head and neck cancer; Leiomyosarcoma; Liposarcoma; Lung cancer; Non-small cell lung cancer; Osteosarcoma; Pancreatic cancer; Sarcoma; Skin cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- 14 Apr 2023 Status changed from active, no longer recruiting to completed.
- 27 Apr 2022 Planned End Date changed from 31 Mar 2022 to 31 Mar 2023.
- 27 Apr 2022 Planned primary completion date changed from 31 Mar 2022 to 31 Mar 2023.